Overview
OncoDNA offers NGS testing solutions including OncoDEEP® (solid biopsy), OncoSELECT® (liquid biopsy), and clinical data intelligence platforms. The company serves oncology laboratory professionals, pharma companies, and healthcare institutions to guide treatment decisions and precision patient enrollment.
Funding & milestones
3 events found for OncoDNA · 2016–2023
Series AVenture / equity1 sourceEUR 7.7M
Reported amount EUR 7,700,000
Participating investor Ackermans & van Haaren announces EUR 7.7m equity; later company history rounds this to EUR 8m.
InvestorsAckermans & van HaarenSeries BVenture / equity1 sourceEUR 19M
Reported amount EUR 19,000,000
Investor-hosted company release confirms completed EUR 19m Series B.
InvestorsVesalius Biocapital IIISwisscanto InvestSFPI-FPIMCPH BankInventuresSambrinvestSofinimSRIWSeries CVenture / equity1 sourceEUR 6.5M
Reported amount EUR 6,500,000
Company release announces EUR 6.5m Series C, entirely subscribed by existing shareholders.
InvestorsWallonie EntreprendreVesalius BioCapital IIIAckermans & van HaarenSwisscantoCPH BankSFPISambrinvest
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Key people
In the news
- OncoDNA is launching its first roundtable dedicated to oncology genomic reporting in Dublin 🇮🇪. Organised with the support of Healthcare Innovation Consortium, this exclusive event will bring together digital, bioinformatics, scientific and clinical leaders to exchange perspectives, identify current challenges and help shape the future of genomic reporting. The insights gathered during the evening will contribute to a jointly authored white paper outlining what genomic reports need to deliver to remain clinically relevant and fit
- 𝗖𝗮𝗻 𝗰𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 𝗯𝗲 𝗯𝗼𝘁𝗵 𝗿𝗼𝗯𝘂𝘀𝘁 𝗮𝗻𝗱 𝗰𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲? Our application note demonstrates the strong performance of the OncoDEEP® DNA Kit on MGI’s sequencing platforms. The combined technologies delivered high-quality sequencing data for the detection of clinically relevant genomic variants and fusions. Most importantly, they achieved 100% concordance in the reporting of key genomic signatures: 🧬 Tumour Mutational Burden (TMB) 🧬 Microsatellite
- 𝗪𝗲'𝗿𝗲 𝗰𝗼𝘂𝗻𝘁𝗶𝗻𝗴 𝗱𝗼𝘄𝗻 𝘁𝗼 𝗘𝗦𝗠𝗢 𝟮𝟬𝟮𝟲. Every advance in precision oncology starts with a conversation — between researchers, clinicians, and the teams turning tumor biology into answers patients can act on. That's exactly what ESMO means to us: a chance to sit down with the people shaping cancer care, share where our science stands today, and hear what challenges oncology professionals are still working to solve. Our team will be on-site all weekend, ready to walk you through our latest diagnostic
- 𝗪𝗵𝗮𝘁 𝗶𝗳 𝘆𝗼𝘂𝗿 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘆 𝗰𝗼𝘂𝗹𝗱 𝗿𝗲𝗽𝗹𝗮𝗰𝗲 𝗮 𝟱𝟬𝟬+ 𝗴𝗲𝗻𝗲 𝗽𝗮𝗻𝗲𝗹, 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝗛𝗥𝗥/𝗛𝗥𝗗 𝗮𝘀𝘀𝗮𝘆𝘀 𝗮𝗻𝗱 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗳𝗼𝗰𝘂𝘀𝗲𝗱 𝗽𝗮𝗻𝗲𝗹𝘀 𝘄𝗶𝘁𝗵 𝗼𝗻𝗲 𝗰𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗮𝗻𝗱 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗰𝗼𝘃𝗲𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗲𝗻𝘁𝗶𝗿𝗲 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄? Managing several NGS pipelines, from wet-lab processing to clinical reporting, can be complex, resource-intensive and time-consuming. To streamline its operations, MVZ Pathologie Trier chose to
- 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗮 𝗹𝗶𝗾𝘂𝗶𝗱 𝗯𝗶𝗼𝗽𝘀𝘆? Diagnosing cancer has usually meant surgery or a needle biopsy. But a growing tumour is constantly leaving traces in the bloodstream — and we're getting very good at reading them. In this short carousel, we explain from scratch what a liquid biopsy is, and when it can make the difference. 👇 You want to go deeper? Read our white paper "The Liquid Biopsy Blueprint (Part 1) — Liquid Biopsy & Minimal Residual Disease in Oncology." 📖 https://lnkd.in/eTTrkwDr #LiquidBiopsy
- 𝗢𝗻𝗰𝗼𝗗𝗡𝗔 𝗶𝘀 𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝗘𝗦𝗠𝗢 𝟮𝟬𝟮𝟲. Precision oncology doesn't happen overnight. It's built through years of collaboration, clinical evidence, and a relentless focus on turning complex tumor biology into decisions that matter for patients. From the clinical trials and research partnerships that have shaped our journey to the solutions we now deliver to laboratories, hospitals and clinicians worldwide, our expertise has been built one milestone at a time, bringing precision oncology ever closer to the
- 𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝗮 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝗿𝗲𝗽𝗼𝗿𝘁 𝗻𝗲𝗲𝗱 𝘁𝗼 𝗯𝗲 𝘁𝗿𝘂𝗹𝘆 𝗳𝗶𝘁 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲? A patient’s cancer journey is written into their DNA, how we unlock, interpret and communicate that story matters. On 14 October 2026, in Dublin, OncoDNA will bring together digital, bioinformatics, scientific and clinical leaders to co-author a white paper on the future of genomic reporting, over dinner at The Ivy. Healthcare professionals from across Ireland and Northern Ireland are invited to register. Places
- 𝗪𝗵𝘆 𝘄𝗼𝘂𝗹𝗱 𝘆𝗼𝘂 𝗰𝗵𝗼𝗼𝘀𝗲 𝘁𝗼 𝘄𝗼𝗿𝗸 𝘄𝗶𝘁𝗵 𝗢𝗻𝗰𝗼𝗗𝗡𝗔? We know that our customers choose to work with us because we build trust based on real connections. Since 2024, OncoDNA has chosen to bring its customer community together annually in a welcoming environment that encourages transparent open scientific discussions, multiprofessional collaboration, and the sharing of experience around the use of our products, this gives our customers an opportunity to learn from one another and for us to capture valuable
Alumni 2 went on to found or lead
Christophe Van HuffelNorth-American Pharma Business Prospection→Co-Founder and CSO at OncoRNA
Jean-Pol DetiffeFounder & CEO→co-Founder OncoRNA www.oncorna.eu at OncoRNA
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.